CY1109826T1 - Μεθοδοι για την βελτιωση της βιοδιαθεσιμοτητας ενος αναστολεα ρενινης - Google Patents

Μεθοδοι για την βελτιωση της βιοδιαθεσιμοτητας ενος αναστολεα ρενινης

Info

Publication number
CY1109826T1
CY1109826T1 CY20101100019T CY101100019T CY1109826T1 CY 1109826 T1 CY1109826 T1 CY 1109826T1 CY 20101100019 T CY20101100019 T CY 20101100019T CY 101100019 T CY101100019 T CY 101100019T CY 1109826 T1 CY1109826 T1 CY 1109826T1
Authority
CY
Cyprus
Prior art keywords
improving
renini
bio
availability
steel
Prior art date
Application number
CY20101100019T
Other languages
Greek (el)
English (en)
Inventor
Gian P Camenisch
Gerhard Gross
Isabel Ottinger
Daniel Wasmuth
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35056890&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109826(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109826T1 publication Critical patent/CY1109826T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CY20101100019T 2004-08-03 2010-01-05 Μεθοδοι για την βελτιωση της βιοδιαθεσιμοτητας ενος αναστολεα ρενινης CY1109826T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59870004P 2004-08-03 2004-08-03
EP05769973A EP1776099B1 (en) 2004-08-03 2005-08-02 Methods for improving bioavailability of a renin inhibitor

Publications (1)

Publication Number Publication Date
CY1109826T1 true CY1109826T1 (el) 2014-09-10

Family

ID=35056890

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20101100019T CY1109826T1 (el) 2004-08-03 2010-01-05 Μεθοδοι για την βελτιωση της βιοδιαθεσιμοτητας ενος αναστολεα ρενινης

Country Status (31)

Country Link
US (1) US7709532B2 (https=)
EP (2) EP1776099B1 (https=)
JP (1) JP5134366B2 (https=)
KR (1) KR20070040384A (https=)
CN (1) CN1993116B (https=)
AR (1) AR050043A1 (https=)
AT (1) ATE449601T1 (https=)
AU (1) AU2005268844B2 (https=)
BR (1) BRPI0514021A (https=)
CA (1) CA2572743C (https=)
CY (1) CY1109826T1 (https=)
DE (1) DE602005017905D1 (https=)
DK (1) DK1776099T3 (https=)
EC (1) ECSP077169A (https=)
ES (1) ES2335597T3 (https=)
HR (1) HRP20100064T1 (https=)
IL (1) IL180678A (https=)
MA (1) MA28821B1 (https=)
MX (1) MX2007001339A (https=)
MY (1) MY142180A (https=)
NO (1) NO20071142L (https=)
NZ (1) NZ552903A (https=)
PE (1) PE20060416A1 (https=)
PL (1) PL1776099T3 (https=)
PT (1) PT1776099E (https=)
RU (1) RU2404758C2 (https=)
SI (1) SI1776099T1 (https=)
TN (1) TNSN07038A1 (https=)
TW (1) TW200616610A (https=)
WO (1) WO2006013094A1 (https=)
ZA (1) ZA200610639B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
EP1927350A1 (en) * 2006-11-24 2008-06-04 Novartis AG Methods for improving bioavailability of a renin inhibitor
CA2769392A1 (en) 2009-07-31 2011-02-03 Sandoz Ag Method for the preparation of w-amino-alkaneamides and w-amino-alkanethioamides as well as intermediates of this method
WO2012010651A2 (en) 2010-07-23 2012-01-26 Sandoz Ag Method for the preparation of omega-amino-alkaneamides and omega-amino-alkanethioamides as well as intermediates of this method
WO2014168255A1 (ja) * 2013-04-12 2014-10-16 国立大学法人京都大学 巨核球の成熟化促進物質
WO2015035218A1 (en) * 2013-09-05 2015-03-12 Howard University Method of increasing the bioavailability of an hiv drug
JP6029621B2 (ja) * 2014-07-14 2016-11-24 ヤマサ醤油株式会社 血漿レニン活性の測定法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL108499A (en) 1993-02-04 2000-02-29 Lilly Co Eli Mammalian influx peptide transporter
US5567592A (en) 1994-02-02 1996-10-22 Regents Of The University Of California Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal
MY119161A (en) * 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
CA2224227A1 (en) 1995-06-07 1996-12-19 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5716928A (en) * 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CN1143680C (zh) * 1997-08-14 2004-03-31 阿旺蒂斯制药公司 增强非索非那定及其衍生物之生物利用度的方法
JP2003512443A (ja) * 1999-10-27 2003-04-02 ベーカー ノートン ファーマシューティカルズ インコーポレイテッド タキサンをヒト患者に経口投与するための方法及び組成物
AU3808801A (en) * 2000-02-11 2001-08-20 Praecis Pharmaceuticals Incorporated Methods for enhancing the bioavailability of a drug
WO2001092468A2 (en) * 2000-05-31 2001-12-06 Rutgers, The State University Of New Jersey Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
KR20040066177A (ko) 2001-12-19 2004-07-23 알자 코포레이션 친수성 거대분자의 경구 생체이용률을 증가시키기 위한제형 및 투여 형태
US6869970B2 (en) * 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
EP1501546B1 (de) * 2002-05-03 2012-10-10 Hexal AG Stabile pharmazeutische formulierung für eine kombination aus einem statin mit einem ace-hemmer
PT1517682E (pt) * 2002-06-28 2007-02-28 Speedel Pharma Ag Formulação farmacêutica compreendendo inibidor da renina não-peptídico e tensioactivo
NZ549535A (en) * 2004-03-17 2010-11-26 Novartis Ag Use of aliskiren for treating renal and other disorders

Also Published As

Publication number Publication date
CN1993116B (zh) 2011-04-13
JP2008508340A (ja) 2008-03-21
US20080108703A1 (en) 2008-05-08
MY142180A (en) 2010-10-15
AR050043A1 (es) 2006-09-20
DK1776099T3 (da) 2010-03-01
KR20070040384A (ko) 2007-04-16
ZA200610639B (en) 2008-05-28
ECSP077169A (es) 2007-02-28
PL1776099T3 (pl) 2010-05-31
CN1993116A (zh) 2007-07-04
IL180678A0 (en) 2008-03-20
RU2404758C2 (ru) 2010-11-27
US7709532B2 (en) 2010-05-04
MX2007001339A (es) 2007-03-27
HRP20100064T1 (hr) 2010-03-31
EP1776099B1 (en) 2009-11-25
ATE449601T1 (de) 2009-12-15
DE602005017905D1 (de) 2010-01-07
TNSN07038A1 (en) 2008-06-02
PT1776099E (pt) 2010-01-06
AU2005268844A1 (en) 2006-02-09
CA2572743A1 (en) 2006-02-09
JP5134366B2 (ja) 2013-01-30
IL180678A (en) 2011-04-28
CA2572743C (en) 2012-12-04
WO2006013094A1 (en) 2006-02-09
RU2007107850A (ru) 2008-09-10
EP1776099A1 (en) 2007-04-25
SI1776099T1 (sl) 2010-03-31
MA28821B1 (fr) 2007-08-01
AU2005268844B2 (en) 2009-03-05
ES2335597T3 (es) 2010-03-30
NZ552903A (en) 2010-09-30
TW200616610A (en) 2006-06-01
EP2191823A1 (en) 2010-06-02
PE20060416A1 (es) 2006-06-09
NO20071142L (no) 2007-04-26
BRPI0514021A (pt) 2008-05-27

Similar Documents

Publication Publication Date Title
CY1109826T1 (el) Μεθοδοι για την βελτιωση της βιοδιαθεσιμοτητας ενος αναστολεα ρενινης
CY1124144T1 (el) Συνθεσεις και μεθοδοι για θεραπεια εγκεφαλικου επεισοδιου σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
CY1113494T1 (el) 8-ΕΤΕΡΟΑΡΥΛΟ-3-ΑΛΚΥΛΟ-1,3-ΔΙΥΔΡΟ-ΙΜΙΔΑΖΟ[4,5-c]ΚΙΝΟΛΙΝ-2-ΟΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ ΡΙ-3
CY1110162T1 (el) Φαρμακοτεχνικη μορφη και μεθοδοι για την αγωγη της θρομβοκυτταραιμιας
CY1115745T1 (el) Συνθεσεις και μεθοδοι για αντιμετωπιση ή προληψη σχετιζομενης με οξαλικα νοσου
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
CY1115059T1 (el) Θεραπευτικα απταμερη χρησιμα στην θεραπευτικη αγωγη διαταραχων σχετιζομενων με συμπληρωμα
CY1117959T1 (el) 24-norudca για την αγωγη αυτοανοσης ηπατιτιδας
NO20051345L (no) Humane anti-IFN-gamma noytraliserende antistoffer som selektive IFN-gamma reaksjonsvei inhibitorer
CY1113963T1 (el) Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ανταγωνιστες ακτιβινης-actriia και χρηση αυτων στην προληψη η' θεραπευτικη αγωγη πολλαπλου μυελωματος
CY1117177T1 (el) Διεργασια για την παρασκευη [(3-υδροξυπυριδινο-2-καρβονυλ)αμινο]αλκανοϊκων οξεων, εστερων και αμιδιων
NO2014005I1 (no) olodaterol, syreaddisjonssalter og farmakologisk akseptable syrer derav
CY1108092T1 (el) Ενωσεις και μεθοδοι για την αναστολη της μιτωτικης προοδου με την αναστολη της κινασης aurora
CY1110775T1 (el) Υποκατεστημενα αμιδια του θειενοπυρρολιου του καρβοξυλικου οξεος, αμιδια της πυρρολοθειαζολης του καρβοξυλικου οξεος και σχετικα αναλογα ως αναστολεις της κινασης i εψιλον της καζεϊνης
CY1112451T1 (el) Μεθοδος για μειωση γαστρεντερικης τοξικοτητας λογω της χορηγησης τεγκαφουρης
CY1114735T1 (el) Θεραπευτικες συνθεσεις οι οποιες περιεχουν εναν ειδικο ανταγωνιστη του υποδοχεα της ενδοθηλινης και εναν αναστολεα της pde5
CY1114468T1 (el) Ροφλουμιλαστη για τη θεραπεια της πνευμονικης υπερτασης
ATE432281T1 (de) Pyrrolotriazin-kinasehemmer
CY1114811T1 (el) Νεα κλασματα πρωτεϊνων γαλακτος και η χρηση τους για την προληψη ή τη θεραπεια των χρονιων φλεγμονωδων νοσων
CY1109154T1 (el) Μικροκαψουλες για την καθυστερημενη και ελεγχομενη απελευθερωση της περινδοπριλης
MX2009005247A (es) Metodos para mejorar la biodisponibilidad de un inhibidor de renina.